Reprise Biomedical

Reprise Biomedical, Inc. is focused on the development and commercialization of biological medical devices which offer advanced solutions for healing. Reprise was established as a spin-off from Miromatrix Medical Inc. in July 2019 and took ownership of the manufacturing, marketing, and distribution for two commercially available products, MiroDerm biologic wound matrix and MiroFlex biologic matrix for soft tissue reinforcement. The company is committed to innovation using our proprietary perfusion decellularization technology to develop new medical devices which address unmet surgical needs for healing. Our newest product, Miro3D wound matrix, is an example of that commitment. Miro3D broadens our wound management...

Biotech,biotechnology,decellularization,biologics,innovation,and medical device

Reprise biomedical operates in the Biotechnology research industry.

Reprise biomedical's revenue is 11m - 100m

Reprise biomedical has 11 - 50 employees.